CN Patent

CN114401716A — 持续释放的曲前列环素-化合物微粒组合物

Assigned to Nanomi BV · Expires 2022-04-26 · 4y expired

What this patent protects

本文提供了包括新颖微粒的新型组合物，所述新颖微粒被配置成在施用于哺乳动物受试者时提供一种或多种曲前列环素化合物的长效释放。本发明的所述微粒是生物相容的并且通常可通过针或其它注射系统注射。本发明还提供了使用此类组合物的方法，如在治疗肺动脉高压中。

USPTO Abstract

本文提供了包括新颖微粒的新型组合物，所述新颖微粒被配置成在施用于哺乳动物受试者时提供一种或多种曲前列环素化合物的长效释放。本发明的所述微粒是生物相容的并且通常可通过针或其它注射系统注射。本发明还提供了使用此类组合物的方法，如在治疗肺动脉高压中。

Drugs covered by this patent

Patent Metadata

Patent number
CN114401716A
Jurisdiction
CN
Classification
—
Expires
2022-04-26
Drug substance claim
No
Drug product claim
No
Assignee
Nanomi BV
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.